Viatris to Acquire Pacira BioSciences for $1.65 Billion in Cash
Viatris to Acquire Pacira BioSciences for $1.65 Billion in Cash
Viatris has agreed to acquire all outstanding shares of Pacira BioSciences for $36.50 per share in cash, an aggregate equity value of $1.65 billion, via a tender offer followed by a second-step merger. Pacira's EXPAREL (bupivacaine liposome injectable suspension) and ZILRETTA (triamcinolone acetonide extended-release injectable suspension) generated approximately $746 million in total revenue and $177 million in adjusted EBITDA in the twelve months ended June 30, 2026. The deal is expected to close by the end of 2026 and be immediately accretive to Viatris' financial guidance metrics.
Viatris will fund the transaction mainly from excess cash with the remainder from short-term borrowings, adding high-margin, patent-protected non-opioid pain products to its innovative medicines portfolio and its meloxicam opportunity.
Key facts
| Companies | Viatris Inc., Pacira BioSciences, Inc. |
|---|---|
| Chemicals | bupivacaine liposome, triamcinolone acetonide, meloxicam |
| Investment | $1.65 billion aggregate equity value ($36.50 per share in cash) |
| Timing | 2026-10-08, 2026-06-30 (twelve months ended, Pacira financials), by end of 2026 (expected closing), 2026-11-05 (Viatris third-quarter 2026 results) |
| Partners | Pacira BioSciences, Inc., Viatris Inc. |
| End uses | post-surgical pain management, osteoarthritis knee pain, non-opioid pain therapies |
Market context
Bupivacaine liposome and triamcinolone acetonide extended-release formulations are long-acting local anesthetic and corticosteroid products used to manage pain without relying on opioids, mainly after surgery and for osteoarthritis knee pain. Demand is driven by hospitals, ambulatory surgery centers, orthopedic practices and pain clinics that want to reduce opioid use and shorten recovery times. Products of this type rely on proprietary drug delivery technology, so patent protection and manufacturing know-how carry significant value. Acquisitions of specialty pain assets like these can tighten competition in the non-opioid segment, shift contracting and pricing dynamics among hospital buyers, and push generic and branded pharmaceutical makers to expand their own pain portfolios. For chemical and API suppliers, such deals matter mainly through changes in sourcing relationships and the manufacturing footprint of the combined company, rather than through immediate shifts in bulk chemical supply or commodity prices.
Source: official release on newsroom.viatris.com. Summary and context written by Market Krystal.
About Viatris
Pharma & biotech.
Need the market behind this story?
Market Krystal can send a report sample or a scope for this chemical, company or market. An analyst replies within 24 hours.